Literature DB >> 26154183

Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.

Pedram Gerami1, Oriol Yélamos2, Christina Y Lee2, Roxana Obregon2, Pedram Yazdan2, Lauren M Sholl2, Gerta E Guitart2, Ching-Ni Njauw3, Hensin Tsao3.   

Abstract

IMPORTANCE: Several kindreds having germline BAP1 mutations with a propensity for uveal and cutaneous melanomas and other internal malignancies have been described in an autosomal dominant tumor predisposition syndrome. However, clinically atypical moles have not been previously recognized as a component of this syndrome, to our knowledge. We describe the first kindred to date with a germline mutation in BAP1 associated with multiple cutaneous melanomas and classic dysplastic nevus syndrome. OBSERVATIONS: We describe a 53-year-old man who was initially seen in 2003 with dysplastic nevus syndrome, multiple atypical melanocytic proliferations showing loss of immunostaining for BAP1, and 7 cutaneous melanomas. Germline testing was performed in the proband, his 16-year-old son, and his 13-year-old daughter, revealing a germline mutation in the BAP1 gene (c.592G>T, p.Glu198X) in the proband and in his 16-year-old son. CDKN2A and CDK4 genes were wild type. No members of this kindred reported a history of uveal melanoma. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first report of a patient with multiple melanomas, dysplastic nevus syndrome, and an inactivating germline BAP1 mutation. The coexistence of dysplastic nevus syndrome and a BAP1 germline mutation extends the spectrum of the BAP1 tumor predisposition syndrome and may confer a greater risk for cutaneous melanomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154183      PMCID: PMC5831190          DOI: 10.1001/jamadermatol.2015.1701

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  13 in total

1.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

2.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

3.  A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.

Authors:  Thomas Wiesner; Rajmohan Murali; Isabella Fried; Lorenzo Cerroni; Klaus Busam; Heinz Kutzner; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2012-06       Impact factor: 6.394

Review 4.  Melanoma susceptibility genes and risk assessment.

Authors:  Alexander Marzuka-Alcalá; Michele Jacobs Gabree; Hensin Tsao
Journal:  Methods Mol Biol       Date:  2014

5.  BAP1 and cancer.

Authors:  Michele Carbone; Haining Yang; Harvey I Pass; Thomas Krausz; Joseph R Testa; Giovanni Gaudino
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

6.  Ambiguous melanocytic tumors with loss of 3p21.

Authors:  Iwei Yeh; Thaddeus W Mully; Thomas Wiesner; Swapna S Vemula; Sonia A Mirza; Alyssa J Sparatta; Timothy H McCalmont; Boris C Bastian; Philip E LeBoit
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

7.  Germline mutations in BAP1 predispose to melanocytic tumors.

Authors:  Thomas Wiesner; Anna C Obenauf; Rajmohan Murali; Isabella Fried; Klaus G Griewank; Peter Ulz; Christian Windpassinger; Werner Wackernagel; Shea Loy; Ingrid Wolf; Agnes Viale; Alex E Lash; Mono Pirun; Nicholas D Socci; Arno Rütten; Gabriele Palmedo; David Abramson; Kenneth Offit; Arthur Ott; Jürgen C Becker; Lorenzo Cerroni; Heinz Kutzner; Boris C Bastian; Michael R Speicher
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

8.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

9.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

10.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

View more
  4 in total

Review 1.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.

Authors:  Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

2.  Novel insights into the BAP1-inactivated melanocytic tumor.

Authors:  Michele Donati; Petr Martinek; Petr Steiner; Petr Grossmann; Tomas Vanecek; Liubov Kastnerova; Isabel Kolm; Martina Baneckova; Pietro Donati; Irina Kletskaya; Antonina Kalmykova; Josef Feit; Petr Blasch; Diana Szilagyi; Alfonso Baldi; Paolo Persichetti; Anna Crescenzi; Michal Michal; Dmitry V Kazakov
Journal:  Mod Pathol       Date:  2021-12-02       Impact factor: 7.842

3.  Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.

Authors:  Oriol Yélamos; Cristián Navarrete-Dechent; Michael A Marchetti; Tova Rogers; Zoe Apalla; Philippe Bahadoran; Nuria Blázquez-Sánchez; Klaus Busam; Cristina Carrera; Stephen W Dusza; Arnaud de la Fouchardière; Gerardo Ferrara; Pedram Gerami; Harald Kittler; Aimilios Lallas; Josep Malvehy; José F Millán-Cayetano; Kelly C Nelson; Victor Li Quan; Susana Puig; Howard Stevens; Luc Thomas; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2018-09-20       Impact factor: 11.527

4.  Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

Authors:  Thomas P Potjer; Sander Bollen; Anneliese J E M Grimbergen; Remco van Doorn; Nelleke A Gruis; Christi J van Asperen; Frederik J Hes; Nienke van der Stoep
Journal:  Int J Cancer       Date:  2019-01-21       Impact factor: 7.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.